MARKET

PRQR

PRQR

ProQR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.47
+0.23
+2.79%
After Hours: 8.48 +0.01 +0.12% 17:41 09/17 EDT
OPEN
8.09
PREV CLOSE
8.24
HIGH
8.71
LOW
7.93
VOLUME
698.05K
TURNOVER
--
52 WEEK HIGH
9.46
52 WEEK LOW
3.400
MARKET CAP
560.10M
P/E (TTM)
-7.0613
1D
5D
1M
3M
1Y
5Y
Implied Volatility Surging for ProQR (PRQR) Stock Options
Investors need to pay close attention to ProQR (PRQR) stock based on the movements in the options market lately.
Zacks · 4d ago
Eli Lilly Reports In 13G Filing A 5.6% Stake In ProQR Therapeutics
-SEC Filing
SEC Filing · 09/10 17:10
48 Biggest Movers From Yesterday
Gainers
Benzinga · 09/10 09:16
Why ProQR Therapeutics's Stock Is Trading Higher Today
ProQR Therapeutics's (NASDAQ:PRQR) shares are trading higher after the company announced Axiomer RNA editing licensing and research collaboration with Lilly.
Benzinga · 09/09 17:50
Hot Stocks: BIIB Alzheimer’s woes; CRDF, CNTA clinical trial data; PRQR partnership deal; RKLB jumps on earnings
Biotech and drug development news dominated Thursday's midday action. This included Biogen (NASDAQ:BIIB), which dropped to a multi-month low after its CEO warned of slower-than-expected adoption of its controversial Alzheimer’s
Seekingalpha · 09/09 17:11
INGN, MTEX and AVCT among mid-day movers
Gainers: Gevo (NASDAQ:GEVO) +35%. American Virtual Cloud Technologies (NASDAQ:AVCT) +33%. Rocket Lab (NASDAQ:RKLB) +32%. Torrid (NYSE:CURV) +30%. Montauk (NASDAQ:MNTK) +25%. Impel (NASDAQ:IMPL) +22%. Gold Royalty (NYSE:GROY) +22%. ProQR (NASDAQ:PRQR) +21%.
Seekingalpha · 09/09 17:00
ProQR Therapeutics, Centessa Pharmaceuticals leads healthcare gainers; Humanigen, Invacare among major losers
Gainers: ProQR Therapeutics (NASDAQ:PRQR) +22%, Centessa Pharmaceuticals (NASDAQ:CNTA) +22%, Kiromic BioPharma (NASDAQ:KRBP) +19%, Trinity Biotech (NASDAQ:TRIB) +16%, Enveric Biosciences (NASDAQ:ENVB) +14%. Losers: Humanigen (NASDAQ:HGEN) -54%, Invacare (N...
Seekingalpha · 09/09 14:59
Benzinga Pro's Top 5 Stocks To Watch For Thursday, Sept. 9, 2021: ORCL, GME, HYZN, SAM, PRQR
Today's 5 Stock Ideas:  Oracle (ORCL) - Oracle reports Q1 earnings results on Monday, September 13th. GameStop (GME) - Shares down ~11% premarket. The company reported Q2 earnings results
Benzinga · 09/09 12:59
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRQR. Analyze the recent business situations of ProQR through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRQR stock price target is 24.69 with a high estimate of 36.73 and a low estimate of 16.88.
EPS
Institutional Holdings
Institutions: 88
Institutional Holdings: 42.06M
% Owned: 63.61%
Shares Outstanding: 66.13M
TypeInstitutionsShares
Increased
15
1.12M
New
20
2.15M
Decreased
16
2.33M
Sold Out
21
5.78M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman - Supervisory/Independent Director
Dinko Valerio
Chairman - Management/Chief Executive Officer
Daniel De Boer
Independent Director/Supervisory Board
Bart Filius
Independent Director/Supervisory Board
Theresa Heggie
Independent Director/Supervisory Board
Alison Lawton
Independent Director/Supervisory Board
Antoine Papiernik
Independent Director/Supervisory Board
James Shannon
No Data
About PRQR
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

Webull offers kinds of ProQR Therapeutics NV stock information, including NASDAQ:PRQR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRQR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRQR stock methods without spending real money on the virtual paper trading platform.